Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 7/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32676015 | 0.92 | HPGD (0.62) | AKR1C3MEN1KMT2AMAPTLMNA | |
| SCHEMBL32676006 | 0.84 | ALDH1A1 (0.63) | MEN1KMT2AMAPTLMNASMN1; SMN2 | |
| SCHEMBL30835869 | 0.84 | ALDH1A1 (0.62) | MEN1KMT2AMAPTLMNASMN1; SMN2 | |
| SCHEMBL30835871 | 0.77 | ALDH1A1 (0.55) | MEN1KMT2AMAPTLMNASMN1; SMN2 | |
| SCHEMBL32676014 | 0.76 | ALDH1A1 (0.49) | MEN1KMT2AMAPTLMNASMN1; SMN2 | |
| SCHEMBL32676007 | 0.75 | ALDH1A1 (0.51) | MEN1KMT2AMAPTLMNASMN1; SMN2 | |
| SCHEMBL32676012 | 0.75 | ALDH1A1 (0.51) | MEN1KMT2AMAPTLMNASMN1; SMN2 | |
| SCHEMBL32676017 | 0.74 | LMNA (0.50) | MEN1KMT2AMAPTLMNASMN1; SMN2 | |
| SCHEMBL32676009 | 0.74 | ALDH1A1 (0.70) | MEN1KMT2AMAPTLMNASMN1; SMN2 | |
| SCHEMBL30835951 | 0.74 | MAPT (0.49) | MEN1KMT2AMAPTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049064-A1 | PROTEIN:PROTEIN INTERACTION INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2026-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049064-A1 | PROTEIN:PROTEIN INTERACTION INHIBITORS | PRMT6, PRMT5, PRMT1 | AKR1C3 4260/4885MEN1 3416/4885KMT2A 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.